Chemomab Therapeutics Ltd. — Director's Dealing 2021

Mar 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Anchiano Therapeutics Ltd. (ANCN)
CIK: 0001534248
Period of Report: 2020-04-23

Reporting Person: Polovets Stanislav (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-16	Stock Option (right to buy)	$0.17	A	55000	Acquired	2030-07-15	Ordinary Shares (55000)	Direct

Footnotes

F1: 25% of shares underlying the option vests on July 16, 2021, and 12.5% of the remaining shares underlying the option vest in eight equal quarterly installments thereafter.